Cedar Pollen Allergy - Pipeline Review, H2 2018

Cedar Pollen Allergy - Pipeline Review, H2 2018


  • Products Id :- GMDHC10813IDB
  • |
  • Pages: 38
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Cedar Pollen Allergy-Pipeline Review, H2 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cedar Pollen Allergy-Pipeline Review, H2 2018, provides an overview of the Cedar Pollen Allergy (Immunology) pipeline landscape.

Cedar allergy is a seasonal allergy brought on by an allergic reaction to the pollen from mountain cedar trees. Symptoms include runny nose, itchy and watery eyes, nasal blockage and sneezing. Some suffers also complain of fatigue, mild headache, facial discomfort, sore throat, partial loss of smell and the sensation of ear plugging. Treatment includes antihistamines and decongestants.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Cedar Pollen Allergy-Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Cedar Pollen Allergy (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Cedar Pollen Allergy (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Cedar Pollen Allergy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Preclinical stages are 1, 2 and 1 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively.

Cedar Pollen Allergy (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Cedar Pollen Allergy (Immunology).

- The pipeline guide reviews pipeline therapeutics for Cedar Pollen Allergy (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Cedar Pollen Allergy (Immunology) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Cedar Pollen Allergy (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Cedar Pollen Allergy (Immunology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Cedar Pollen Allergy (Immunology).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Cedar Pollen Allergy (Immunology) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Cedar Pollen Allergy-Overview

Cedar Pollen Allergy-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Cedar Pollen Allergy-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Cedar Pollen Allergy-Companies Involved in Therapeutics Development

Astellas Pharma Inc

F. Hoffmann-La Roche Ltd

REGiMMUNE Corp

Stallergenes Greer plc

Cedar Pollen Allergy-Drug Profiles

ASP-4070-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Biologic for Cedar Pollen Allergy-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

omalizumab-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RGI-1001-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

STG-120-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cedar Pollen Allergy-Dormant Projects

Cedar Pollen Allergy-Discontinued Products

Cedar Pollen Allergy-Product Development Milestones

Featured News & Press Releases

Mar 09, 2015: Immunomic Therapeutics to Present at BIO-Europe Annual Conference

Feb 20, 2015: Immunomic Therapeutics to Present Data on Its Proprietary LAMP Vaccine Platform at 2015 American Academy of Allergy, Asthma and Immunology Meeting

Apr 24, 2013: Immunomic Therapeutics Announces Interim Data Analysis Of Phase I Study To Treat Japanese Red Cedar Allergy

Nov 08, 2012: Immunomic Therapeutics Doses First Patient In Phase I Clinical Trial Of JRC-LAMP-Vax Vaccine To Treat Japanese Red Cedar Allergy

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Figures

Number of Products under Development for Cedar Pollen Allergy, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018

List of Tables

Number of Products under Development for Cedar Pollen Allergy, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Cedar Pollen Allergy-Pipeline by Astellas Pharma Inc, H2 2018

Cedar Pollen Allergy-Pipeline by F. Hoffmann-La Roche Ltd, H2 2018

Cedar Pollen Allergy-Pipeline by REGiMMUNE Corp, H2 2018

Cedar Pollen Allergy-Pipeline by Stallergenes Greer plc, H2 2018

Cedar Pollen Allergy-Dormant Projects, H2 2018

Cedar Pollen Allergy-Discontinued Products, H2 2018

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Astellas Pharma Inc

F. Hoffmann-La Roche Ltd

REGiMMUNE Corp

Stallergenes Greer plc

Cedar Pollen Allergy Therapeutic Products under Development, Key Players in Cedar Pollen Allergy Therapeutics, Cedar Pollen Allergy Pipeline Overview, Cedar Pollen Allergy Pipeline, Cedar Pollen Allergy Pipeline Assessment

select a license
Single User License
USD 2000 INR 142780
Site License
USD 4000 INR 285560
Corporate User License
USD 6000 INR 428340

NEWSLETTER BY CATEGORY




Testimonials

The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com